2-(2-Chloro-6-fluoroanilino)-2-(3-methylphenyl)acetic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-(2-Chloro-6-fluoroanilino)-2-(3-methylphenyl)acetic acid
• 化学式: C₁₅H₁₃ClFNO₂
• 分子量: 293.72
• InChiKey: FUIUYVVZEHFUFD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• Methods and compositions for treatment of cancer pain
  申请人：Novartis AG

  公开号：EP1767199A2

  公开（公告）日：2007-03-28

  The invention provides a method of treating cancer pain, e.g. bone cancer pain, in a subject in need of such treatment which comprises administering to the subject an effective amount of a COX-2 inhibitor; advantageously a compound of formula I wherein R, R1, R2, R3, R4, and R5 are as defined; a pharmaceutically acceptable salts thereof; or a pharmaceutically acceptable prodrug ester thereof.

  本发明提供了一种治疗癌症疼痛（如骨癌疼痛）的方法，该方法包括向需要治疗的受试者施用有效量的 COX-2 抑制剂；最好是式 I 的化合物 其中 R、R1、R2、R3、R4 和 R5 如所定义；其药学上可接受的盐；或其药学上可接受的原药酯。
• Pharmaceutical use of cox-2-inhibitors in angiogenesis-mediated ocular disorders
  申请人：Brazzell Kimbro Romulus

  公开号：US20050043410A1

  公开（公告）日：2005-02-24

  The invention provides a method of treating an angiogenesis-mediated ocular disorder, e.g. ocular neovascularisation, retinal neovascularisation, including neovascularisation following injury or infection, retrolental fibroplasias, and neovascular glaucoma, age-related macular degeneration, diabetic retinopathy, pathologic myopia, ocular histoplasmosis, neovascular glaucoma, retinopathy of prematurity, the after effects of corneal transplantation, control of postsurgical ocular inflammation (e.g. after cataract surgery), cystoid macular edema (CME), herpes keratitis, in a subject in need of such treatment which comprises administering to the subject an effective amount of a COX-2 inhibitor of formula I wherein R, R 1 , R 2 , R 3 , R 4 , and R 5 are as defined; a pharmaceutically acceptable salts thereof; or a pharmaceutically acceptable prodrug esters thereof.

  本发明提供了一种治疗血管生成介导的眼部疾病的方法，例如眼部新生血管、视网膜新生血管（包括损伤或感染后的新生血管）、后叶纤维增生症、新生血管性青光眼、老年性黄斑变性、糖尿病视网膜病变、病理性近视、眼组织胞浆菌病、新生血管性青光眼、早产儿视网膜病变、角膜移植后遗症、控制手术后眼部炎症（如白内障手术后）、囊样黄斑水肿（CME）、疱疹性角膜炎（CME）等。在需要此类治疗的受试者中，包括向受试者施用有效量的式 I COX-2 抑制剂，其中 R、R 1 , R 2 , R 3 , R 4 和 R 5 如所定义；其药学上可接受的盐；或其药学上可接受的原药酯。
• METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER PAIN
  申请人：Novartis AG

  公开号：EP1501491A2

  公开（公告）日：2005-02-02
• METHODS USING A COMBINATION OF A 3-HETEROARYL-2-INDOLINONE AND A CYCLOOXYGENASE-2 INHIBITOR FOR THE TREATMENT OF NEOPLASIA
  申请人：Pharmacia Corporation

  公开号：EP1509224A1

  公开（公告）日：2005-03-02
• PHARMACEUTICAL USE OF COX-2 INHIBITORS IN ANGIOGENESIS-MEDIATED OCULAR DISORDERS
  申请人：Novartis AG

  公开号：EP1503746A1

  公开（公告）日：2005-02-09